Peter Sever
Peter Sever
Professor of Clinical Pharmacology, Imperial College London
Potvrđena adresa e-pošte na
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ...
New England journal of medicine 376 (18), 1713-1722, 2017
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian …
PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ...
The Lancet 361 (9364), 1149-1158, 2003
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the …
B Dahlöf, PS Sever, NR Poulter, H Wedel, DG Beevers, M Caulfield, ...
The Lancet 366 (9489), 895-906, 2005
Genetic studies of body mass index yield new insights for obesity biology
AE Locke, B Kahali, SI Berndt, AE Justice, TH Pers, FR Day, C Powell, ...
Nature 518 (7538), 197-206, 2015
Treatment of hypertension in patients 80 years of age or older
NS Beckett, R Peters, AE Fletcher, JA Staessen, L Liu, D Dumitrascu, ...
New England Journal of Medicine 358 (18), 1887-1898, 2008
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
CT Trialists
The Lancet 376 (9753), 1670-1681, 2010
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
BPLT Trialists’Collaboration, F Turnbull
Lancet 362 (9395), 1527-1535, 2003
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
PM Rothwell, SC Howard, E Dolan, E O'Brien, JE Dobson, B Dahlöf, ...
The Lancet 375 (9718), 895-905, 2010
Defining the role of common variation in the genomic and biological architecture of adult human height
AR Wood, T Esko, J Yang, S Vedantam, TH Pers, S Gustafsson, AY Chu, ...
Nature genetics 46 (11), 1173-1186, 2014
Interpretation of the evidence for the efficacy and safety of statin therapy
R Collins, C Reith, J Emberson, J Armitage, C Baigent, L Blackwell, ...
The Lancet 388 (10059), 2532-2561, 2016
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV
B Williams, NR Poulter, MJ Brown, M Davis, GT McInnes, JF Potter, ...
Journal of human hypertension 18 (3), 139-185, 2004
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
E Evangelou, HR Warren, D Mosen-Ansorena, B Mifsud, R Pazoki, H Gao, ...
Nature genetics 50 (10), 1412-1425, 2018
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
B Williams, TM MacDonald, S Morant, DJ Webb, P Sever, G McInnes, ...
The Lancet 386 (10008), 2059-2068, 2015
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
B Williams, NR Poulter, MJ Brown, M Davis, GT McInnes, JF Potter, ...
Bmj 328 (7440), 634-640, 2004
Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke
PM Rothwell, SC Howard, E Dolan, E O'Brien, JE Dobson, B Dahlöf, ...
The Lancet Neurology 9 (5), 469-480, 2010
Effect of spironolactone on blood pressure in subjects with resistant hypertension
N Chapman, J Dobson, S Wilson, B Dahlof, PS Sever, H Wedel, ...
hypertension 49 (4), 839-845, 2007
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
DI Swerdlow, D Preiss, KB Kuchenbaecker, MV Holmes, JEL Engmann, ...
The Lancet 385 (9965), 351-361, 2015
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
JL Mega, NO Stitziel, JG Smith, DI Chasman, MJ Caulfield, JJ Devlin, ...
The Lancet 385 (9984), 2264-2271, 2015
Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial
ML O’Donoghue, S Fazio, RP Giugliano, ESG Stroes, E Kanevsky, ...
Circulation 139 (12), 1483-1492, 2019
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20